We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing of drugs that address diseases with high unmet medical need. Tenax has secured the North American rights to develop and commercialize levosimendan from the originator company, Orion Corporation of Espoo Finland. Levosimendan is a calcium sensitizer and K-ATP channel opener that works through a unique triple mechanism of action. It is approved in over 60 countries as an intravenous treatment for acute decompensated heart failure. However, levosimendan is not available in the United States or in Canada. Tenax plans to advance the development of Levosimendan for the treatment of pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF). Tenax plans to initiate a Phase 2 trial in PH-HFpEF patients in the next few months.